- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04442269
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
February 29, 2024 updated by: Regeneron Pharmaceuticals
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA).
The secondary objectives of the study are:
- To evaluate the effects of dupilumab on exacerbations in participants with ABPA
- To evaluate the effects of dupilumab on ABPA-related exacerbations
- To evaluate the effects of dupilumab on hospitalization/emergency department (ED)/urgent care visits in participants with ABPA
- To evaluate the effects of dupilumab on asthma control in participants with ABPA
- To evaluate the effects of dupilumab on health-related quality of life (HRQoL) in participants with ABPA
- To evaluate the effects of dupilumab on serum total immunoglobulin E (IgE) and Aspergillus-specific IgE concentrations
- To evaluate the effects of dupilumab on Fractional exhaled Nitric Oxide (FeNO) levels
- To evaluate safety and tolerability of dupilumab in participants with ABPA
- To evaluate dupilumab concentrations in serum and the incidence of anti-dupilumab antibodies in participants with ABPA
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Haskovo, Bulgaria, 6305
- Regeneron Study Site
-
Razgrad, Bulgaria, 7200
- Regeneron Study Site
-
Smolyan, Bulgaria, 4700
- Regeneron Study Site
-
Sofia, Bulgaria, 1142
- Regeneron Study Site
-
-
-
-
-
Brest, France, 29609
- Regeneron Study Site
-
Lyon, France, 69004
- Regeneron Study Site
-
Marseille, France, 13015
- Regeneron Study Site
-
Montpellier, France, 34295
- Regeneron Study Site
-
Paris, France, 75018
- Regeneron Study Site
-
Rennes, France, 35033
- Regeneron Study Site
-
Tours, France, 37044
- Regeneron Study Site
-
-
-
-
-
Berlin, Germany, 10717
- Regeneron Study Site
-
Frankfurt am Main, Germany, 60389
- Regeneron Study Site
-
-
Saxony
-
Leipzig, Saxony, Germany, 4357
- Regeneron Study Site
-
-
-
-
-
Budapest, Hungary, 1083
- Regeneron Study Site
-
-
-
-
-
Fukuyama, Japan, 7200001
- Regeneron Study Site
-
Kanagawa, Japan, 259-1193
- Regeneron Study Site
-
Nagoya, Japan, 454-8509
- Regeneron Study Site
-
Naka-gun, Japan, 3191113
- Regeneron Study Site
-
Sakai, Japan, 591-8555
- Regeneron Study Site
-
Yanagawa, Japan, 8320059
- Regeneron Study Site
-
Yokohama, Japan, 231-8682
- Regeneron Study Site
-
-
-
-
-
Arnhem, Netherlands, 6815
- Regeneron Study Site
-
Breda, Netherlands, 4818 CK
- Regeneron Study Site
-
Eindhoven, Netherlands, 5623
- Regeneron Study Site
-
Zutphen, Netherlands, 7207
- Regeneron Study Site
-
-
North Holland
-
Amsterdam, North Holland, Netherlands, 1105AZ
- Regeneron Study Site
-
-
-
-
-
Bialystok, Poland, 15-044
- Regeneron Study Site
-
Gdansk, Poland, 80402
- Regeneron Study Site
-
-
-
-
-
Brasov, Romania, 500051
- Regeneron Study Site
-
-
Bihor
-
Oradea, Bihor, Romania, 410169
- Regeneron Study Site
-
-
-
-
England
-
Leicester, England, United Kingdom, LE39QP
- Regeneron Study Site
-
Liverpool, England, United Kingdom, L7 8XP
- Regeneron Study Site
-
London, England, United Kingdom, E1 2EF
- Regeneron Study Site
-
London, England, United Kingdom, SW3 6NP
- Regeneron Study Site
-
Wythenshawe, England, United Kingdom, M23 9LT
- Regeneron Study Site
-
-
West Yorkshire
-
Bradford, West Yorkshire, United Kingdom, BD96RJ
- Regeneron Study Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Regeneron Study Site
-
-
Arizona
-
Scottsdale, Arizona, United States, 85251
- Regeneron Study Site
-
-
California
-
Bakersfield, California, United States, 93301
- Regeneron Study Site
-
La Jolla, California, United States, 92093
- Regeneron Study Site
-
Los Angeles, California, United States, 90025
- Regeneron Study Site
-
Riverside, California, United States, 92506
- Regeneron Study Site
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Regeneron Study Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Regeneron Study Site
-
-
New York
-
Bronx, New York, United States, 10461
- Regeneron Study Site
-
New York, New York, United States, 10032
- Regeneron Study Site
-
-
Ohio
-
Columbus, Ohio, United States, 43235
- Regeneron Study Site
-
-
Pennsylvania
-
DuBois, Pennsylvania, United States, 15801
- Regeneron Study Site
-
Philadelphia, Pennsylvania, United States, 19140
- Regeneron Study Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Diagnosis of both ABPA and asthma
- On a maintenance therapy for their asthma with controller medication which must include inhaled corticosteroids (ICS) and may include 1 or more additional controller medications including a long-acting beta agonist (LABA), leukotriene receptor antagonist (LTRA), and/or long-acting muscarinic receptor antagonist (LAMA), etc for at least 12 weeks, with a stable dose and regimen with no change in the dose or frequency of administration for at least 4 weeks prior to the screening visit and between the screening and baseline/randomization visits
- For participants on OCS (oral corticosteroid): must be on a chronic stable dose (no change in the dose) of OCS of up to 10 mg/day (for participants taking daily corticosteroids) or up to 30 mg every alternate day (for participants taking alternate day corticosteroids) (prednisone/prednisolone or the equivalent) for at least 4 weeks prior to the screening visit and between the screening and the baseline/randomization visit
- Must have experienced ≥1 severe respiratory exacerbation requiring treatment with systemic corticosteroids or hospitalization or treatment in ED/urgent care within 12 months prior to the screening visit or must be receiving chronic stable low-dose OCS per above criteria
Key Exclusion Criteria:
- Weight less than 30.0 kilograms
- Current smoker or e-cigarette user, cessation of smoking or e-cigarette use within 6 months prior to randomization, or >=10 pack-years smoking history
- Post-bronchodilator FEV1 <30% predicted normal at screening
- Respiratory exacerbation requiring systemic corticosteroids within 4 weeks prior to screening and between screening and baseline visit (for patients on daily or alternate day OCS, exacerbation requiring at least double the maintenance dose of corticosteroids)
- Upper or lower respiratory tract infection within the 4 weeks prior to screening (visit 1) or between the screening and randomization visits
- Significant chronic pulmonary disease other than asthma complicated with ABPA (eg, physician-diagnosed bronchiectasis due to a condition other than ABPA; cystic fibrosis; sarcoidosis; interstitial lung disease not due to ABPA; chronic obstructive pulmonary disease [COPD] not due to ABPA; hypereosinophilic syndrome; etc), a diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts
- Diagnosis or suspected diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) (also called Churg-Strauss Syndrome)
NOTE: Other protocol defined inclusion / exclusion criteria applies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dupilumab
Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)
|
Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
Other Names:
|
Experimental: Placebo
Matching dupilumab without active substance
|
Matching placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) compared to placebo
Time Frame: At Week 24
|
At Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentrations of functional dupilumab in serum by treatment regimen
Time Frame: Up to 64 Weeks
|
Up to 64 Weeks
|
|
Annualized rate of severe respiratory exacerbations
Time Frame: Over the 24 to 52 Week Treatment Period
|
Defined as new onset of symptoms or clinical worsening of respiratory symptoms requiring systemic corticosteroid treatment for ≥3 consecutive days; for patients who are on maintenance systemic corticosteroids, at least double the dose of maintenance systemic corticosteroids for ≥3 consecutive days (with or without antibiotic therapy if indicated)
|
Over the 24 to 52 Week Treatment Period
|
Annualized rate of ABPA-related exacerbations
Time Frame: Over the 24 to 52 Week Treatment Period
|
Defined as severe respiratory exacerbations (as defined above) that are associated with a doubling of serum total Immunoglobulin E (IgE) from the prior pre-exacerbation value.
|
Over the 24 to 52 Week Treatment Period
|
Annualized rate of severe respiratory exacerbations requiring either hospitalization or observation for >24 hours in an ED/urgent care facility
Time Frame: Over the 24 to 52 Week Treatment Period
|
Over the 24 to 52 Week Treatment Period
|
|
Change from baseline in Asthma Control Questionnaire (ACQ)-5
Time Frame: Over the 24 to 52 Week Treatment Period
|
ACQ is completed by patient to measure both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment.
The ACQ-5 score is the mean of the first 5 questions, between 0 (totally controlled) and 6 (severely uncontrolled).
A higher score indicates lower asthma control.
Patients with a score below 1.0 reflect adequately controlled asthma and patients with scores above 1.0 reflect inadequately controlled asthma.
The optimal cut-point score of 1.50 should be used to be confident that a patient has inadequately controlled asthma.
|
Over the 24 to 52 Week Treatment Period
|
Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score
Time Frame: Over the 24 to 52 Week Treatment Period
|
SGRQ will be completed by the patient to measure and quantify health status in adult patients with chronic airflow limitation.
Total score ranges from 0 to 100.
Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial).
Lower score indicates better Quality of Life (QoL).
|
Over the 24 to 52 Week Treatment Period
|
Percentage of participants achieving a reduction in the SGRQ score of 4 points or greater from baseline
Time Frame: Up to 52 Weeks
|
SGRQ will be completed by the patient to measure and quantify health status in adult patients with chronic airflow limitation.
Total score ranges from 0 to 100.
Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial).
Lower score indicates better Quality of Life (QoL).
|
Up to 52 Weeks
|
Percent change from baseline in total IgE in serum
Time Frame: Over the 24 to 52 Week Treatment Period
|
Over the 24 to 52 Week Treatment Period
|
|
Percent change from baseline in A fumigatus-specific IgE in serum
Time Frame: Over the 24 to 52 Week Treatment Period
|
Over the 24 to 52 Week Treatment Period
|
|
Percent change from baseline in fractional exhaled nitric oxide (FeNO)
Time Frame: Over the 24 to 52 Week Treatment Period
|
Over the 24 to 52 Week Treatment Period
|
|
Absolute change from baseline in FeNO
Time Frame: Over the 24 to 52 Week Treatment Period
|
Over the 24 to 52 Week Treatment Period
|
|
Incidence of treatment-emergent adverse events (TEAEs) from baseline
Time Frame: Through the end of the 52 Week Treatment Period
|
Through the end of the 52 Week Treatment Period
|
|
Incidence of treatment-emergent anti-drug antibody (ADA) responses and titer over time
Time Frame: Up to 64 Weeks
|
Up to 64 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2020
Primary Completion (Actual)
July 27, 2023
Study Completion (Actual)
February 9, 2024
Study Registration Dates
First Submitted
June 4, 2020
First Submitted That Met QC Criteria
June 19, 2020
First Posted (Actual)
June 22, 2020
Study Record Updates
Last Update Posted (Estimated)
March 4, 2024
Last Update Submitted That Met QC Criteria
February 29, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bacterial Infections and Mycoses
- Respiratory Hypersensitivity
- Hypersensitivity
- Mycoses
- Lung Diseases, Fungal
- Aspergillosis
- Pulmonary Aspergillosis
- Aspergillosis, Allergic Bronchopulmonary
Other Study ID Numbers
- R668-ABPA-1923
- 2019-002619-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD Sharing Time Frame
Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
IPD Sharing Access Criteria
Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Bronchopulmonary Aspergillosis
-
Postgraduate Institute of Medical Education and...CompletedAllergic Bronchopulmonary AspergillosesIndia
-
University Hospital, MontpellierCompletedSevere Asthma | Allergic Bronchopulmonary Aspergillosis (ABPA)France
-
Postgraduate Institute of Medical Education and...RecruitingAllergic Bronchopulmonary Aspergillosis | Chronic Pulmonary AspergillosisIndia
-
University Hospital, BordeauxCompletedAllergic Bronchopulmonary AspergillosesFrance
-
Shanghai Zhongshan HospitalNot yet recruitingAllergic Bronchopulmonary Aspergillosis
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruiting
-
Postgraduate Institute of Medical Education and...Cipla Ltd.CompletedAllergic Bronchopulmonary AspergillosisIndia
-
Post Graduate Institute of Medical Education and...RecruitingAllergic Bronchopulmonary AspergillosisIndia
-
Postgraduate Institute of Medical Education and...Active, not recruiting
-
Postgraduate Institute of Medical Education and...CompletedAllergic Bronchopulmonary AspergillosisIndia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States